{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:58:36Z","timestamp":1779357516658,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier","isbn-type":[{"value":"9780443222429","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["51-2021"],"award-info":[{"award-number":["51-2021"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["IDEAS211016AJON"],"award-info":[{"award-number":["IDEAS211016AJON"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016120","name":"Departamento de Salud, Gobierno de Navarra","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["FPU18\/02638"],"award-info":[{"award-number":["FPU18\/02638"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.mcb.2024.03.010","type":"book-chapter","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:53:28Z","timestamp":1713455608000},"page":"33-38","source":"Crossref","is-referenced-by-count":2,"title":["A mouse model to assess immunotherapy-related colitis"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.mcb.2024.03.010_bb0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0015","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000585","article-title":"Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma","volume":"5","author":"Favara","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): Evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0030","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0040","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0045","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/1078-0432.CCR-16-0081","article-title":"A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases","volume":"23","author":"Montfort","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0050","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s43018-022-00410-0","article-title":"The expanding palette of immunotherapy research","volume":"3","author":"No authors listed","year":"2022","journal-title":"Nature Cancer"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0060","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/bs.mcb.2024.03.010_bb0065","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/nprot.2017.044","article-title":"Chemically induced mouse models of acute and chronic intestinal inflammation","volume":"12","author":"Wirtz","year":"2017","journal-title":"Nature Protocols"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2024.03.010_bb0075","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa1709684","article-title":"Nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"The New England Journal of Medicine"}],"container-title":["Methods in Cell Biology","Animal Models of Disease - Part C"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X24001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X24001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:49:14Z","timestamp":1762231754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091679X24001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443222429"],"references-count":14,"URL":"https:\/\/doi.org\/10.1016\/bs.mcb.2024.03.010","relation":{},"ISSN":["0091-679X"],"issn-type":[{"value":"0091-679X","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}